SOD1 and amyotrophic lateral sclerosis: This work highlights the unexplored possibilities of mutation-specific personalized therapy for SOD1–ALS and the potential use of a CCS-mimetic polytherapy specifically targeting steps on the SOD1 PTM maturation pathway.